Brie Carter

Tamboran Resources (ASX:TBN) announced the appointment of Todd Abbott as CEO, effective Jan. 15.

CLINUVEL Pharmaceuticals (ASX:CUV) has begun dosing in a preclinical study of its controlled-release injectable peptide platform, VLRX-L.

Radiopharm Theranostics (ASX:RAD) has increased its ownership stake in Radiopharm Ventures, a joint venture with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%.

A United States lawmaker has introduced new legislation aimed at restricting political prediction market trading by government insiders following a high-profile wager linked to Venezuela’s leadership.

Bitcoin (CRYPTO:BTC) began 2026 with renewed momentum as bullish sentiment returned across futures markets and spot trading volumes increased.

Evolus (NASDAQ:EOLS), a global performance beauty company dedicated to building a differentiated aesthetic portfolio, announced preliminary, unaudited net revenue results for the fourth quarter and full year ended December 31, 2025, along with updated forward-looking guidance.

Amazon Pharmacy (NASDAQ:AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, now offers Novo Nordisk’s Wegovy® pill, the first and only FDA-approved oral GLP-1 for weight management, through many insurance plans as well as a transparent cash-pay option.

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it has entered into an exclusive global license agreement with Pfizer (NYSE:PFE) for ervogastat (formerly PF-06865571), an oral diacylglycerol acyltransferase 2 (DGAT-2) inhibitor currently in Phase 2 development, as well as rights to two additional early-stage metabolic dysfunction-associated steatohepatitis (MASH) assets.

Aquestive Therapeutics (NASDAQ:AQST) reported that the U.S. Food and Drug Administration has identified deficiencies in the new drug application for Anaphylm (dibutepinephrine), an oral sublingual film formulation for the emergency treatment of Type I allergic reactions, including anaphylaxis.

Sanuwave Health (NASDAQ:SNWV) reported preliminary fourth-quarter revenue that reached an all-time high, as the medical device maker effectively navigated a volatile reimbursement landscape that has left many of its competitors in the wound-care sector reeling.